ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) WITH ADAPTED FLAMSA CAN CURE HALF OF THE PEDIATRIC PATIENTS WITH REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTS (HSCT) WITH ADAPTED FLAMSA CAN CURE HALF OF THE PEDIATRIC PATIENTS WITH REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML)

Introduction: AML represents 20% of the pediatric acute leukemias and 40% of the patients succumb to refractory disease, relapse, or treatment-related toxicities. Patients with refractory disease have the worst outcomes and are usually referred to exclusive palliative care. HSCT in patients with act...

Full description

Bibliographic Details
Main Authors: ACR Correa, AF Martins, ACR Donatelli, CN Santos, MF Cardoso, LL Quintino, G Zamperlini, LDS Domingues, AVL Sousa, A Seber
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Hematology, Transfusion and Cell Therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2531137923011768

Internet

http://www.sciencedirect.com/science/article/pii/S2531137923011768

Similar Items